Skip to main content
Fig. 1 | Respiratory Research

Fig. 1

From: Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol

Fig. 1

Analysis of time to first CID event (ITT population). *p < 0.05, **p < 0.01, ***p < 0.001. The risk of a first CID event was analyzed using a Cox-Proportional Hazard model including study, treatment group, and smoking status as covariates. AB, aclidinium bromide; CID, clinically important deterioration; FF, formoterol fumarate; HR, hazard ratio

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us